Search
Quinagolide
go.drugbank.com/drugs/DB09097ApprovedWithdrawnNewer dopamine receptor agonists such as quinagolide and [DB00248] are shown to effectively inhibit prolactin secretion with improved efficacy over [DB01200].
Tretinoin
go.drugbank.com/drugs/DB00755ApprovedInvestigationalNutraceuticalTretinoin, also known as all-trans-retinoic acid (ATRA), is a naturally occurring derivative of vitamin A (retinol). It is an oxidation product in the physiological pathway of vitamin A metabolism. In human circulation, tretinoin is norm...
Leptin
go.drugbank.com/drugs/DB05098InvestigationalThus, obesity develops when people take in more energy than they use over a prolonged period of time, and this excess food intake is not driven by hunger signals, occurring in spite of the anti-appetite
Caprospinol
go.drugbank.com/drugs/DB05263ExperimentalCaprospinol (SP-233) is the first drug ever to demonstrate the correlation of clearing beta-amyloid from the brain. It also improves the brain histopathology and recovers memory function.
Ferrous aspartate
go.drugbank.com/drugs/DB13220ExperimentalThe use of ferrous acetate over ferrous sulfate is currently undergoing an investigation by a clinical trial [L5464]. It is also used for dying of fabric or leather and as a wood preservative.
MLN8054
go.drugbank.com/drugs/DB13061InvestigationalMLN8054 has been used in trials studying the treatment of Colon Neoplasm, Breast Neoplasm, Bladder Neoplasm, Pancreatic Neoplasm, and Advanced Malignancies.
Tecovirimat
go.drugbank.com/drugs/DB12020ApprovedInvestigational[A35131,A35143] Tecovirimat was approved by the FDA in July 2018 as the first drug ever approved to treat smallpox.
Toloxatone
go.drugbank.com/drugs/DB09245ExperimentalToloxatone is an antidepressant agent, the first ever use of which was in France, 1984. It acts as a selective and reversible inhibitor of monoamine oxidase-A (MOA) [L1388].
DP-VPA
go.drugbank.com/drugs/DB05821InvestigationalDP-VPA is D-Pharm's proprietary lipid modified version of valproic acid (VPA) that demonstrate that DP-VPA is well-tolerated in patients with resistant epilepsy and has a marked effect on reducing seizure frequency.